<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160703</url>
  </required_header>
  <id_info>
    <org_study_id>207872</org_study_id>
    <nct_id>NCT03160703</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices</brief_title>
  <official_title>A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the stain build up of two stannous
      fluoride (SnF2) / sodium tripolyphosphate (STP) dentifrices of differing abrasivity levels,
      with a marketed standard fluoride dentifrice and a marketed SnF2 dentifrice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proof of principal (PoP) single centre, randomised, examiner blind, four-treatment arm,
      parallel design study will be used to evaluate and compare the stain buildup of two 0.454%
      SnF2/ 5% STP dentifrices of differing abrasivity levels, with a marketed standard fluoride
      dentifrice and a marketed SnF2 dentifrice. Stain will be assessed following a full
      professional dental prophylaxis, at intervals over a 4 week treatment period, using an
      established clinical measure of extrinsic dental stain - the MacPherson modification of the
      Lobene stain index (MLSI). Participants will be stratified by pre-prophylaxis MLSI score
      (total MLSI Area x Intensity (AÃ—I) for the facial surfaces of the 12 anterior teeth) and
      smoking status. The study will be conducted in healthy participants with a propensity for
      extrinsic dental stain (in the opinion of the examiner) on the facial surfaces of the
      anterior teeth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Actual">August 25, 2017</completion_date>
  <primary_completion_date type="Actual">August 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single centre, randomised, examiner blind, parallel design study to evaluate the buildup of extrinsic dental stain over a 4 week treatment period</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI after usage of the allocated study dentifrice, after 4 weeks twice daily use. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Extrinsic Dental Stain</condition>
  <condition>Oral Hygiene</condition>
  <arm_group>
    <arm_group_label>Test dentifrice 1 (RDA~58)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test dentifrice 2 (RDA~77)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference dentifrice 1 (RDA~80)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference dentifrice 2 (RDA~120)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will apply dentifrice containing 0.454% SnF2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica</intervention_name>
    <description>Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.</description>
    <arm_group_label>Test dentifrice 1 (RDA~58)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)</intervention_name>
    <description>Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.</description>
    <arm_group_label>Test dentifrice 2 (RDA~77)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80</intervention_name>
    <description>Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.</description>
    <arm_group_label>Reference dentifrice 1 (RDA~80)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stannous fluoride (SnF2, 0.454%), RDA~120</intervention_name>
    <description>Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.</description>
    <arm_group_label>Reference dentifrice 2 (RDA~120)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study procedures, restrictions and willingness to
             participate as evidenced by voluntary written informed consent and has received a
             signed and dated copy of the informed consent form.

          -  Understands and is willing, able and likely to comply with all study procedures and
             restrictions.

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee: No clinically significant and relevant abnormalities of medical
             history or oral examination which could impact study outcomes, Absence of any
             condition that would impact on subject safety or wellbeing, or affect the subject's
             ability to understand and follow study procedures and requirements.

          -  In the opinion of the investigator or medically qualified designee, At screening: Good
             oral health, at least 16 natural teeth including the 12 anterior teeth, the facial
             surfaces, and mandibular lingual surfaces, of at least 11 of the 12 anterior teeth,
             gradable for the MLSI, presence of extrinsic dental stain (judged to be formed due to
             dietary factors, or use of tobacco products) on the facial surfaces of the anterior
             teeth, as determined from a visual stain assessment. At baseline: A sufficient level
             of extrinsic dental stain (in the opinion of the examiner) on the facial surfaces of
             the scorable anterior (maxillary and mandibular) teeth.

        Exclusion Criteria:

          -  Women who are known to be pregnant, or who are intending to become pregnant over the
             duration of the study. Since this study is not being conducted under an IND this
             information will be self-reported, and not diagnosed through the conduct of urinary
             pregnancy testing.

          -  Women who are breast-feeding.

          -  Recent history (within the last year) of alcohol or other substance abuse.

          -  Concurrent Medication: Current regular use of mouthwashes containing ingredients that
             are known to impart staining. For example, chlorhexidine or cetylpyridinium chloride
             (CPC), Use of minocycline, tetracycline or doxycycline within 30 days prior to
             screening, Use of minocycline, tetracycline or doxycycline between the screening and
             baseline visit, Daily doses of a medication and/or traditional/herbal ingredients
             which, in the opinion of the investigator, may affect study outcomes. For example,
             drugs or supplements containing metal ions known to impart staining to the enamel.

          -  Disease: Presence of chronic debilitating disease which, in the opinion of the
             investigator, could affect study outcomes, Any condition which, in the opinion of the
             investigator, causes xerostomia.

          -  Allergy/Intolerance:Known or suspected intolerance or hypersensitivity to the study
             materials (or closely related compounds) or any of their stated ingredients.

          -  Clinical study/Experimental Product:Participation in another clinical study or receipt
             of an investigational drug within 30 days of the screening visit, Previous
             participation in this study.

          -  General dentition exclusions: Dental prophylaxis within 8 weeks of screening, Gross
             periodontal disease, treatment of periodontal disease (including surgery) within 12
             months of screening, scaling or root planning within 3 months of screening, Use of any
             professionally dispensed or over the counter bleaching/ whitening products (excluding
             daily use whitening dentifrices) within the past 3 months.

          -  Specific Dentition Exclusions for Test Teeth: Any tooth which, in the opinion of the
             investigator, appears to be non-vital based on changes in the intrinsic colour, tooth
             with evidence of current or recent caries, or reported treatment of decay in 12 months
             of screening, tooth with exposed dentine which, in the opinion of the investigator,
             could impact grading of extrinsic dental stain; tooth with deep, defective or facial
             restorations; tooth used as an abutment for fixed or removable partial dentures; tooth
             with full crown or veneer, orthodontic bands or cracked enamel, tooth with surface
             irregularities, discoloration due to trauma, tetracycline stain, restorations, or hypo
             or hyperplasic areas which, in the opinion of the investigator, would prevent
             consistent grading of extrinsic dental stain.

          -  Personnel: An employee of the sponsor or the study site or members of their immediate
             family.

          -  Other: Any subject who, in the judgment of the investigator, should not participate in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 0C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <results_first_submitted>July 30, 2018</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 17, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dental stain, stannous fluoride, dentifrice</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Tin Fluorides</mesh_term>
    <mesh_term>Fluorophosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03160703/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03160703/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from one center in Canada.</recruitment_details>
      <pre_assignment_details>A total of 225 participants were screened, of which 220 participants were enrolled and randomized in the study. A total of 5 participants were not randomized in study as 3 participants did not meet study criteria, and 2 withdrew their consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test Dentifrice 1 (RDA~58)</title>
          <description>Participants applied experimental dentifrice containing 0.454 percent (%) stannous fluoride (SnF2) / 5% sodium tripolyphosphate (STP); 2.0% abrasive silica</description>
        </group>
        <group group_id="P2">
          <title>Test Dentifrice 2 (RDA~77)</title>
          <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica</description>
        </group>
        <group group_id="P3">
          <title>Reference Dentifrice 1 (RDA~80)</title>
          <description>Participants applied dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP)</description>
        </group>
        <group group_id="P4">
          <title>Reference Dentifrice 2 (RDA~120)</title>
          <description>Participants applied dentifrice containing 0.454% SnF2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Dentifrice 1 (RDA~58)</title>
          <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica</description>
        </group>
        <group group_id="B2">
          <title>Test Dentifrice 2 (RDA~77)</title>
          <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica</description>
        </group>
        <group group_id="B3">
          <title>Reference Dentifrice 1 (RDA~80)</title>
          <description>Participants applied dentifrice containing 1000 ppm fluoride as SMFP</description>
        </group>
        <group group_id="B4">
          <title>Reference Dentifrice 2 (RDA~120)</title>
          <description>Participants applied dentifrice containing 0.454% SnF2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="10.80"/>
                    <measurement group_id="B2" value="46.1" spread="11.20"/>
                    <measurement group_id="B3" value="48.7" spread="11.50"/>
                    <measurement group_id="B4" value="46.6" spread="12.28"/>
                    <measurement group_id="B5" value="47.7" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4</title>
        <description>An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI after usage of the allocated study dentifrice, after 4 weeks twice daily use. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The Intent-To-Treat (ITT) population (N=219) included all participants who were randomized, received at least 1 dose of investigational product, and had at least 1 post-baseline efficacy evaluation and were reported by randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Dentifrice 1 (RDA~58)</title>
            <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica</description>
          </group>
          <group group_id="O2">
            <title>Test Dentifrice 2 (RDA~77)</title>
            <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica</description>
          </group>
          <group group_id="O3">
            <title>Reference Dentifrice 1 (RDA~80)</title>
            <description>Participants applied dentifrice containing 1000 ppm fluoride as SMFP</description>
          </group>
          <group group_id="O4">
            <title>Reference Dentifrice 2 (RDA~120)</title>
            <description>Participants applied dentifrice containing 0.454% SnF2</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Modified Lobene Stain Index (MLSI) Mean Score at Week 4</title>
          <description>An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI after usage of the allocated study dentifrice, after 4 weeks twice daily use. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The area of stain was scored separately for the gingival and body areas of each assessable tooth on the following scale: 0 - no stain; 1 - stain up to 1/3 of the area affected; 2- stain between 1/3 and 2/3 of the area affected; and 3 - stain more than 2/3 of area affected. Overall MLSI was calculated by multiplying scores of intensity and area, and was thus analyzed on a scale of 0 (best score) to 9 (worst score).</description>
          <population>The Intent-To-Treat (ITT) population (N=219) included all participants who were randomized, received at least 1 dose of investigational product, and had at least 1 post-baseline efficacy evaluation and were reported by randomized treatment.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.423"/>
                    <measurement group_id="O2" value="1.43" spread="0.422"/>
                    <measurement group_id="O3" value="1.42" spread="0.626"/>
                    <measurement group_id="O4" value="1.38" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.078"/>
                    <measurement group_id="O2" value="0.05" spread="0.057"/>
                    <measurement group_id="O3" value="0.10" spread="0.096"/>
                    <measurement group_id="O4" value="0.16" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2681</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0043</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0779</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Statistical significance set at 5% level</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>From ANCOVA with treatment and smoking status as factors and baseline pre-prophylaxis overall MLSI score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>Difference is first named treatment minus second named treatment such that a negative difference favours the first named treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 35 days (28+/- 2 days, maximum 30 days plus 5 days follow up after last use of study product.</time_frame>
      <desc>Safety population (N=220) included all participants who were randomized and received at least one dose of investigational product and was reported by treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Dentifrice 1 (RDA~58)</title>
          <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica</description>
        </group>
        <group group_id="E2">
          <title>Test Dentifrice 2 (RDA~77)</title>
          <description>Participants applied experimental dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica</description>
        </group>
        <group group_id="E3">
          <title>Reference Dentifrice 1 (RDA~80)</title>
          <description>Participants applied dentifrice containing 1000 ppm fluoride as SMFP</description>
        </group>
        <group group_id="E4">
          <title>Reference Dentifrice 2 (RDA~120)</title>
          <description>Participants applied dentifrice containing 0.454% SnF2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

